References
Yao L, Fang F, Wu Q, Zhong Y, Yu L (2010) No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40, 303 subjects. Breast Cancer Res Treat 122:237–242
Listgarten J, Damaraju S, Poulin B, Cook L, Dufour J, Driga A, Mackey J, Wishart D, Greiner R, Zanke B (2004) Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res 10:2725–2737
Zimarina TC, Kristensen VN, Imianitov EN, Bershtein LM (2004) Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer. Mol Biol (Mosk) 38:386–393
Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, Defreese DC, Gramling BA, Evans I, White E (2008) Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 17:1751–1759
Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Perrier ND, Freimanis RI, Allen GO, Rubin P, Sherrill GB, Shaw CS et al (2008) Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 19:1311–1321
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Economopoulos, K.P., Sergentanis, T.N. Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis. Breast Cancer Res Treat 124, 293–294 (2010). https://doi.org/10.1007/s10549-010-1097-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-1097-3